Sangamo Therapeutics, Inc. (SGMO)

Sangamo Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	29.62	41.92	45.2	100.44	178.87	131.33
Short-Term Investments	-	-	35.8	177.19	197.68	510.09
Cash & Short-Term Investments	29.62	41.92	81	277.63	376.55	641.42
Cash Growth	-24.45%	-48.25%	-70.82%	-26.27%	-41.30%	76.96%
Accounts Receivable	0.52	0.53	0.92	3.68	6.01	5.22
Other Receivables	4.6	4.07	3.14	0.79	0.35	1.04
Receivables	5.13	4.6	4.07	4.47	6.36	6.26
Prepaid Expenses	8.42	5.18	9.26	18.22	15.86	11.99
Restricted Cash	0.91	-	-	-	-	-
Total Current Assets	44.08	51.69	94.33	300.33	398.77	659.67
Property, Plant & Equipment	29.22	34.76	52.87	125.53	124.7	112.37
Long-Term Investments	-	-	-	29.85	88.17	50.53
Goodwill	-	-	-	37.55	39.7	42.8
Other Intangible Assets	-	-	-	50.73	53.76	58.13
Long-Term Deferred Tax Assets	-	-	-	1.12	1.06	0.47
Other Long-Term Assets	15.35	15.19	18.13	17.41	15.76	14.58
Total Assets	88.64	101.64	165.32	562.51	721.92	938.55
Accounts Payable	15.56	15.49	15.26	22.42	9.76	12.55
Accrued Expenses	27.01	17.56	16.15	33.39	28.39	30.66
Current Portion of Leases	-	4.31	4.59	4.12	4.03	3.69
Current Unearned Revenue	7.56	7.56	-	51.78	85.71	91.64
Other Current Liabilities	-	0.9	11.73	-	-	5
Total Current Liabilities	50.13	45.81	47.73	111.71	127.89	143.55
Long-Term Leases	25.42	26.25	33.52	38.99	44.06	38.4
Long-Term Unearned Revenue	5.87	5.87	-	109.38	166.78	245.05
Long-Term Deferred Tax Liabilities	-	-	-	6.27	6.65	7.19
Other Long-Term Liabilities	0.98	0.93	1.19	1.21	1.22	7.01
Total Liabilities	82.4	78.87	82.43	267.55	346.58	441.18
Common Stock	3.22	2.13	1.78	1.67	1.46	1.42
Additional Paid-In Capital	1,594	1,532	1,492	1,450	1,334	1,269
Retained Earnings	-1,590	-1,504	-1,406	-1,149	-956.27	-777.98
Comprehensive Income & Other	-1.45	-7.53	-4.6	-8.4	-3.99	5.42
Total Common Equity	6.24	22.77	82.89	294.96	375.34	498.23
Minority Interest	-	-	-	-	-	-0.87
Shareholders' Equity	6.24	22.77	82.89	294.96	375.34	497.37
Total Liabilities & Equity	88.64	101.64	165.32	562.51	721.92	938.55
Total Debt	25.42	30.57	38.1	43.11	48.08	42.09
Net Cash (Debt)	4.19	11.35	42.9	264.37	416.64	649.87
Net Cash Growth	-63.47%	-73.54%	-83.77%	-36.55%	-35.89%	91.19%
Net Cash Per Share	0.02	0.06	0.25	1.71	2.88	4.83
Filing Date Shares Outstanding	336.49	224.71	178.91	168.48	145.97	143.25
Total Common Shares Outstanding	336.49	212.84	178.13	166.79	145.92	142.06
Working Capital	-6.05	5.89	46.6	188.62	270.88	516.12
Book Value Per Share	0.02	0.11	0.47	1.77	2.57	3.51
Tangible Book Value	6.24	22.77	82.89	206.68	281.88	397.31
Tangible Book Value Per Share	0.02	0.11	0.47	1.24	1.93	2.80
Machinery	-	32.78	47.02	54.72	49.85	30.7
Construction In Progress	-	-	1.09	14.77	4.73	12.09
Leasehold Improvements	-	24.92	29.81	30.57	21.97	15.95

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q